LAROTRECTINIB
larotrectinib 100 mg capsule, 56
LAROTRECTINIB (13031W)
13031W
Manner of administration:Oral
Restriction
Indication: Solid tumours (of any type) with confirmed neurotrophic tropomyosin receptor kinase
(NTRK) gene fusion where treatment with this drug is/was initiated in a child
Treatment phase: Initial treatment
Restriction
Indication: Solid tumours (of certain specified types) with confirmed neurotrophic tropomyosin
receptor kinase (NTRK) gene fusion
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 2 | DPMQ: $10,062.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Vitrakvi | |||||